A Phase 2 interventional study of Cemiplimab and Involved-site radiotherapy (IS-RT) in Hodgkin Lymphoma, sponsored by Regeneron Pharmaceuticals. Withdrawn. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-15.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective is to estimate the efficacy of experimental treatment with the anti-PD-1 antibody cemiplimab (REGN2810) in combination with simultaneous or subsequent radiotherapy (RT) in early-stage favorable classical Hodgkin lymphoma (cHL).
Secondary objectives are to assess the safety and feasibility of the 2 experimental strategies.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment Group A
Drug: Cemiplimab · Radiation: Involved-site radiotherapy (IS-RT)
Treatment Group B
Drug: Cemiplimab · Radiation: Involved-site radiotherapy (IS-RT)
Administered in 3-week intervals
Also known as: REGN2810, Libtayo
Patients will receive IS-RT with a dose of 20 Gy. Involved-site radiotherapy will be carried out on the basis of 3D imaging as described in the protocol
Progression-free survival (PFS) at 1 year
Time frame: From randomization up to 1 year
PFS at 2 and 3 years
Time frame: From randomization up to 3 years
Overall survival (OS) at 1, 2, and 3 years
Time frame: From randomization up to 3 years
Incidence of acute toxicities
Time frame: Up to 90 days after study treatment
Rate of patients with long-term fatigue using EORTC-QLQ-FA12
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ). -FA12 module complements the core EORTC QLQ-C30 questionnaire regarding fatigue. Each item can be scored in four dimension on a scale from 1 to 4 with higher scores indicating worse symptoms.
Time frame: 12-18 months after randomization
Rate of patients with long-term fatigue using EORTC-QLQ-C30
Scores range from 0 to 100. A high scale score represents a higher response level.
Time frame: 12-18 months after randomization
Quality of life (QoL) using EORTC-QLQ-30
Scores range from 0 to 100. A high scale score represents a higher response level.
Time frame: Up to 3 years
Rate of early discontinuation of study treatment
Time frame: From first dose to up to 19 weeks
Frequency of lymphoma treatment administered in addition to study treatment
Time frame: From randomization up to 3 years
Types of lymphoma treatment administered in addition to study treatment
Time frame: From randomization up to 3 years
No study locations are listed for this record.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Nov 2020; primary completion for Dec 2022, 25 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemiplimab